September 27, 2011
AstraZeneca K.K. announced on September 26 that it received marketing approval on the same day for its breast cancer treatment Faslodex (fulvestrant) intramuscular injection 250 mg. The drug, which is indicated for postmenopausal metastatic breast cancer, will be launched promptly...read more